JP2014524748A - ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質 - Google Patents

ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質 Download PDF

Info

Publication number
JP2014524748A
JP2014524748A JP2014520658A JP2014520658A JP2014524748A JP 2014524748 A JP2014524748 A JP 2014524748A JP 2014520658 A JP2014520658 A JP 2014520658A JP 2014520658 A JP2014520658 A JP 2014520658A JP 2014524748 A JP2014524748 A JP 2014524748A
Authority
JP
Japan
Prior art keywords
seq
binding protein
antigen binding
antigen
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014520658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524748A5 (enExample
Inventor
エリス，ジョナサン，ヘンリー
モロイ，マイケル，ジェイ
シャー，テジャシュ
トムリンソン，イアン，エム
ヤシン，アーメッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44586854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2014524748(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2014524748A publication Critical patent/JP2014524748A/ja
Publication of JP2014524748A5 publication Critical patent/JP2014524748A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014520658A 2011-07-19 2012-07-19 ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質 Pending JP2014524748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1112429.4 2011-07-19
GBGB1112429.4A GB201112429D0 (en) 2011-07-19 2011-07-19 Antigen-binding proteins with increased FcRn binding
PCT/EP2012/064129 WO2013011076A2 (en) 2011-07-19 2012-07-19 Antigen-binding proteins with increased fcrn binding

Publications (2)

Publication Number Publication Date
JP2014524748A true JP2014524748A (ja) 2014-09-25
JP2014524748A5 JP2014524748A5 (enExample) 2015-08-13

Family

ID=44586854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520658A Pending JP2014524748A (ja) 2011-07-19 2012-07-19 ＦｃＲｎ結合の増加したＴＮＦ−α抗原結合タンパク質

Country Status (22)

Country Link
US (1) US20130243764A1 (enExample)
EP (2) EP2734548B1 (enExample)
JP (1) JP2014524748A (enExample)
KR (1) KR20140054085A (enExample)
CN (1) CN103748110A (enExample)
AU (1) AU2012285786B2 (enExample)
BR (1) BR112014000341A2 (enExample)
CA (1) CA2841105A1 (enExample)
CL (1) CL2014000134A1 (enExample)
CO (1) CO6862106A2 (enExample)
CR (1) CR20140029A (enExample)
DO (1) DOP2014000007A (enExample)
EA (1) EA201391789A1 (enExample)
ES (1) ES2600854T3 (enExample)
GB (1) GB201112429D0 (enExample)
MA (1) MA35345B1 (enExample)
MX (1) MX2014000739A (enExample)
PE (1) PE20141660A1 (enExample)
PH (1) PH12014500167A1 (enExample)
SG (1) SG10201601154QA (enExample)
WO (1) WO2013011076A2 (enExample)
ZA (1) ZA201400062B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017110980A1 (ja) * 2015-12-25 2018-10-18 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
JP2019534001A (ja) * 2016-10-20 2019-11-28 サノフイＳａｎｏｆｉ 抗ｃｈｉｋｖ抗体およびその使用
JP2020506224A (ja) * 2017-01-13 2020-02-27 ハンクス バイオファーマシューティクス，インコーポレイテッド ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法
JP2020511443A (ja) * 2017-03-06 2020-04-16 アレコル リミテッド 液体医薬組成物
US12421322B2 (en) 2017-11-01 2025-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US12522668B2 (en) 2017-09-29 2026-01-13 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
HK1200709A1 (en) 2012-03-07 2015-08-14 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP2015519382A (ja) * 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
LT2892550T (lt) 2012-09-07 2020-04-10 Coherus Biosciences, Inc. Stabilios adalimumabo vandeninės kompozicijos
FR2999431B1 (fr) * 2012-12-17 2016-03-18 Lfb Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
JP6461808B2 (ja) * 2012-12-17 2019-01-30 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 炎症および細菌感染症処置におけるモノクローナル抗体の使用
BR112015017619A2 (pt) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
KR20150129033A (ko) * 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
ES2688726T5 (es) * 2013-07-19 2022-06-27 Hexal Ag Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
JP6526025B2 (ja) * 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
LT2946765T (lt) 2014-05-23 2016-11-25 Ares Trading S.A. Skysta farmacinė kompozicija
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
CA2959629C (en) 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
AR103544A1 (es) * 2015-01-28 2017-05-17 Mabxience S A FORMULACIONES FARMACÉUTICAS PARA ANTICUERPOS ANTI-TNF-a
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
BR112018067897A2 (pt) 2016-03-14 2019-04-24 Univ Oslo imunoglobulinas modificadas com ligação de fcrn alterada
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
AU2017325654B2 (en) 2016-08-02 2024-09-05 Visterra, Inc. Engineered polypeptides and uses thereof
CN110167531B (zh) * 2017-01-11 2025-06-03 赛特瑞恩股份有限公司 稳定的液体调配物
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
US11059892B2 (en) * 2017-08-11 2021-07-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
KR20250008975A (ko) * 2018-01-26 2025-01-16 젠자임 코포레이션 FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체
BR112021017265A2 (pt) * 2019-03-05 2021-12-21 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Agente de edição de dna, população de células de aves, ave quimérica, método para gerar uma ave quimérica e método para induzir letalidade em um embrião macho de uma ave
CN115770292A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的协同免疫及其用途
CN115770291A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用
EP4434517A4 (en) * 2021-11-30 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-sost antibody pharmaceutical composition and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507810A (ja) * 1996-02-09 2000-06-27 ベーアーエスエフ アクツィエンゲゼルシャフト ヒトＴＮＦαに結合するヒト抗体
JP2005501514A (ja) * 2000-12-12 2005-01-20 メディミューン，インコーポレイテッド 延長した半減期を有する分子ならびにその組成物および用途
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
JP2010507670A (ja) * 2006-10-27 2010-03-11 アボツト・バイオテクノロジー・リミテツド 結晶性抗ｈＴＮＦα抗体
JP2011507963A (ja) * 2007-12-26 2011-03-10 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EA022990B1 (ru) 2007-08-20 2016-04-29 Глаксо Груп Лимитед Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок
WO2009068649A2 (en) * 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
WO2009073805A2 (en) * 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
JP5570998B2 (ja) * 2007-12-31 2014-08-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ＴＮＦαに対する抗体
FR2934599B1 (fr) 2008-07-29 2012-12-21 Arkema France Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations
BRPI0919979A2 (pt) * 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
JP2012518398A (ja) * 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
MX2011009362A (es) * 2009-03-05 2011-09-26 Abbott Lab Proteinas de union a il-17.
US20100278822A1 (en) 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
KR20140014405A (ko) * 2009-05-28 2014-02-06 글락소 그룹 리미티드 안구 질병을 치료하거나 예방하는데 사용되는 ｔｎｆ-알파 길항제 및 ｖｅｇｆ 길항제의 조합물
WO2011074965A1 (en) * 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
MX344727B (es) 2010-11-11 2017-01-05 Abbvie Biotechnology Ltd Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507810A (ja) * 1996-02-09 2000-06-27 ベーアーエスエフ アクツィエンゲゼルシャフト ヒトＴＮＦαに結合するヒト抗体
JP2005501514A (ja) * 2000-12-12 2005-01-20 メディミューン，インコーポレイテッド 延長した半減期を有する分子ならびにその組成物および用途
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
JP2010507670A (ja) * 2006-10-27 2010-03-11 アボツト・バイオテクノロジー・リミテツド 結晶性抗ｈＴＮＦα抗体
JP2011507963A (ja) * 2007-12-26 2011-03-10 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"抗体医薬品の体内動態制御に関わる受容体、FcRn.", 日薬理誌, vol. 136, JPN6016012088, 2010, pages 280 - 4, ISSN: 0003288731 *
DALL’ACQUA, WFら: "Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)", J. BIOL. CHEM., vol. 281, no. 33, JPN6016012075, 2006, pages 23514 - 24, ISSN: 0003288723 *
DALL'ACQUA WFら: "Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences.", J. IMMUNOL., vol. 169, no. 9, JPN6016012076, 2002, pages 5171 - 80, ISSN: 0003288724 *
DRUG METAB. DISPOS., vol. 35, no. 1, JPN6016012084, 2007, pages 86 - 94, ISSN: 0003288729 *
DRUG METAB. DISPOS., vol. 38, no. 4, JPN6016012078, 2010, pages 600 - 5, ISSN: 0003288725 *
J. BIOL. CHEM., vol. 279, no. 8, JPN6016012081, 2004, pages 6213 - 6, ISSN: 0003288727 *
J. BIOL. CHEM., vol. 282, no. 3, JPN6016012083, 2007, pages 1709 - 17, ISSN: 0003288728 *
J. IMMUNOL., vol. 176, no. 1, JPN6016012080, 2006, pages 346 - 56, ISSN: 0003288726 *
NAT. BIOTECHNOL., vol. 28, no. 2, JPN6016012086, 2010, pages 157 - 9, ISSN: 0003288730 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168697B2 (en) 2015-12-25 2024-12-17 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies which bind blood coagulation factor VIII and have enhanced activity, and methods of use thereof for treating bleeding and associated conditions
JPWO2017110980A1 (ja) * 2015-12-25 2018-10-18 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
US12460014B2 (en) 2016-04-28 2025-11-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
US12227560B2 (en) 2016-10-20 2025-02-18 Sanofi Anti-CHIKV antibodies and uses thereof
JP7181193B2 (ja) 2016-10-20 2022-11-30 サノフイ 抗ｃｈｉｋｖ抗体およびその使用
JP7181193B6 (ja) 2016-10-20 2022-12-13 サノフイ 抗ｃｈｉｋｖ抗体およびその使用
JP2023015301A (ja) * 2016-10-20 2023-01-31 サノフイ 抗ｃｈｉｋｖ抗体およびその使用
JP2025038079A (ja) * 2016-10-20 2025-03-18 サノフイ 抗ｃｈｉｋｖ抗体およびその使用
JP7664212B2 (ja) 2016-10-20 2025-04-17 サノフイ 抗ｃｈｉｋｖ抗体およびその使用
JP2019534001A (ja) * 2016-10-20 2019-11-28 サノフイＳａｎｏｆｉ 抗ｃｈｉｋｖ抗体およびその使用
JP2020506224A (ja) * 2017-01-13 2020-02-27 ハンクス バイオファーマシューティクス，インコーポレイテッド ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法
JP7220664B2 (ja) 2017-03-06 2023-02-10 アレコル リミテッド 液体医薬組成物
JP2020511443A (ja) * 2017-03-06 2020-04-16 アレコル リミテッド 液体医薬組成物
US12522668B2 (en) 2017-09-29 2026-01-13 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient
US12421322B2 (en) 2017-11-01 2025-09-23 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity

Also Published As

Publication number Publication date
EP2734548B1 (en) 2016-08-17
CN103748110A (zh) 2014-04-23
NZ618897A (en) 2016-02-26
DOP2014000007A (es) 2014-04-30
KR20140054085A (ko) 2014-05-08
PE20141660A1 (es) 2014-11-21
CA2841105A1 (en) 2013-01-24
US20130243764A1 (en) 2013-09-19
EP2734548A2 (en) 2014-05-28
MA35345B1 (fr) 2014-08-01
WO2013011076A2 (en) 2013-01-24
SG10201601154QA (en) 2016-03-30
ES2600854T3 (es) 2017-02-13
ZA201400062B (en) 2017-08-30
EP3009450A1 (en) 2016-04-20
MX2014000739A (es) 2014-02-19
CO6862106A2 (es) 2014-02-10
WO2013011076A3 (en) 2013-04-04
AU2012285786A1 (en) 2014-02-06
AU2012285786B2 (en) 2016-05-12
BR112014000341A2 (pt) 2017-02-14
GB201112429D0 (en) 2011-08-31
EA201391789A1 (ru) 2014-06-30
PH12014500167A1 (en) 2019-03-22
CR20140029A (es) 2014-03-05
CL2014000134A1 (es) 2014-07-25

Similar Documents

Publication Publication Date Title
EP2734548B1 (en) Tnf-alpha-antigen-binding proteins against with increased fcrn binding for use in therapy
AU2014209994B2 (en) TNF-alpha antigen-binding proteins
JP7465382B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP7486421B2 (ja) Ｃｄ２２に結合する重鎖抗体
US20090238820A1 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
AU2018289515A1 (en) Anti-BCMA heavy chain-only antibodies
CN104398471A (zh) 稳定的抗体组合物和用于稳定其的方法
JP7237848B2 (ja) 免疫原性の低下のための方法及び組成物
CN115006517A (zh) Il-21-抗白蛋白单域抗体融合蛋白药物组合物及其用途
US20230406942A1 (en) Igf1r antibodies
NZ618897B2 (en) Tnf-alpha antigen-binding proteins with increased fcrn binding
EP3159007A1 (en) Pharmaceutical composition for treating rheumatoid arthritis
RU2797348C2 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
WO2025221933A9 (en) Antibodies and polypeptides comprising variant fc regions
JP2025502861A (ja) 抗ＦＸＩ／ＦＸＩａ抗体を含む医薬組成物及びその使用
JPWO2021092421A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160617

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160620

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109